# Diabetes Drug Delivery Devices Market Extensive Industry Analysis, Growth Rate, Segmentation, Investment Opportunities and Top Manufacturers 2035 Diabetes management increasingly depends on technologies that allow patients to administer therapy conveniently and consistently. Drug delivery devices such as insulin pumps, pen injectors, autoinjectors and patch-based systems are becoming more sophisticated as manufacturers incorporate connectivity and automation. The diabetes drug delivery devices market was valued at approximately USD 17 billion in 2025 and is projected to reach USD 31 billion by 2030, representing a CAGR of 14.1%. Insulin pumps remain an important part of the market, particularly for patients requiring continuous insulin administration. Pen injectors and other systems can offer portability and simpler administration. Connected devices are becoming increasingly important. Smartphone integration can allow patients to monitor treatment information and, in some systems, control aspects of drug delivery. Closed-loop systems represent another area of innovation. These technologies can integrate glucose monitoring, algorithms and insulin delivery to automate selected aspects of diabetes management. In May 2026, ViCentra announced the commercial launch of its smartphone-controlled Kaleido hybrid closed-loop insulin delivery patch pump system, demonstrating the industry's movement toward connected delivery. More than 80 products are currently marketed or under development across the broader diabetes drug delivery device landscape. Manufacturers are also focusing on reducing needle-related discomfort, simplifying device operation and improving adherence. As diabetes prevalence increases and patients seek more convenient treatment options, connected and minimally invasive delivery systems are likely to see continued adoption. For more information on the Diabetes Drug Delivery Devices Market, visit: https://www.rootsanalysis.com/reports/diabetes-drug-delivery-devices-market.html